Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer (Q38238605)

31 August 2017

title

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer (English)

1 reference

31 August 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109957%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Matthew J Sale

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109957%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

1 August 2014

1 reference

Biochemical Society Transactions

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109957%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109957%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109957%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

776-783

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109957%20AND%20SRC:MED&resulttype=core&format=json

The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Tumour cell survival signalling by the ERK1/2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Progression of RAS-mutant leukemia during RAF inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Identification of a novel inhibitor of mitogen-activated protein kinase kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Oncogenic activating mutations are associated with local copy gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

ERK inhibition overcomes acquired resistance to MEK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140129